COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma

Bookmark and Share
Published: 30 Jun 2020
Views: 119
Rating:
Save
Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Prof Axel Hauschild speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.

He discusses the 5 year final analysis of the COMBI-AD trial looking at the long term benefit of adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600–mutant melanoma.

Prof Hauschild reports that the major finding of this trial is that the relapse free survival after 5 years is still separated between dabrafenib plus trametinib compared to placebo with the difference maintained from year 4 to year 5.

He also notes that the difference in relapse free survival benefit appears across all subgroups that were evaluated.